Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Free Cash Flow (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Free Cash Flow for 10 consecutive years, with -$99.8 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 25.53% to -$99.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$471.0 million through Dec 2025, down 11.88% year-over-year, with the annual reading at -$471.0 million for FY2025, 11.88% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$99.8 million at Ultragenyx Pharmaceutical, down from -$95.5 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$68.1 million in Q2 2022, with the low at -$193.9 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$116.0 million, with a median of -$98.5 million recorded in 2023.
  • The sharpest move saw Free Cash Flow crashed 202.59% in 2021, then soared 55.58% in 2024.
  • Over 5 years, Free Cash Flow stood at -$70.4 million in 2021, then plummeted by 66.66% to -$117.3 million in 2022, then rose by 27.18% to -$85.4 million in 2023, then rose by 6.97% to -$79.5 million in 2024, then fell by 25.53% to -$99.8 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$99.8 million, -$95.5 million, and -$107.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.